期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

关注肿瘤坏死因子-α拮抗剂治疗的皮肤不良反应 被引量：2

原文传递
导出
摘要 肿瘤坏死因子（tumor necrosis factor,TNF）是自然发生的一组独特的细胞因子,具有重要的抗肿瘤和免疫调节作用,其家族中2个不同成员是TNF-α和TNF-β.前者是普遍分布的分子,由不同组织的各种细胞产生 后者主要由激活的淋巴细胞产生,又称淋巴毒素-α.
作者 施桂英
机构地区 解放军总医院风湿科
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2010年第9期585-587,共3页 Chinese Journal of Rheumatology
关键词 肿瘤坏死因子-Α拮抗剂 皮肤不良反应 治疗 免疫调节作用 淋巴毒素-α TNF-Β TNF-α 细胞因子
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献15

  • 1Aikaterini-Evaggelia M,Matekovits A,Dessinioti C,et al.Cutaneous side effects of anti-tumor necrosis factor biologic therapy:a clinical review.J Am Acad Dermatol,2009,61:486-504.
  • 2Borras-Blasco J,Navarro-Ruiz A,Borras C,et al.Adverse cutaneous reactions induced by TNF-α antagonist therapy.Southern Med J,2009,102:1133-1140.
  • 3施桂英.肿瘤坏死因子-α抑制剂诱发银屑病[J].药物不良反应杂志,2007,9(2):103-105. 被引量：3
  • 4Collamer AN,Guerrero KT,Henning JS,et al.Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy:a literature review and potential mechanisms of action.Arthritis Rheum,2008,59:996-1001.
  • 5Wollina U,Hansel G,Koch A,et al.Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata:first 120 cases from the literature including a series of six new patients.Am J Clin Dermatol,2008,9:1-14.
  • 6Ko JM,Gottlieb AB,Kerbleski.JF.Induction and exacerbation of psorlasis with TNF-blockade therapy:a review and analysis of 127 cases.Dermatol Treat,2009,20:100-108.
  • 7Mohan N,Edwards ET,Cupps TR,et al.Leucocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.J Rheumatol,2004,319:1955-1958.
  • 8Ramos-Casals M,Brito-Zeron P,Munoz S,et al.Autoimmune diseases induced by TNF-targeted therapies:analysis of 233 cases.Medicine(Baltimore),2007,86:242-245.
  • 9Deng A,Harvey V,Sina B,et al.Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.Arch Dermatol,2006,142:198-202.
  • 10Voulgari PV,Markatseli TE,Exarchou SA,et al.Granuloma annulare induced by anti-tumor necrosis factor therapy.Ann Rheum Dis,2008,67:567-570.

二级参考文献11

  • 1Mease P J, Antoni CE. Psoriatic arthritis treatment biological modifiers[J]. Ann Rheum Dis, 2005, 64(Suppl2):ii78-ii82.
  • 2Smith CH, Jackson K, Bashir S J, et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, openlabel study[J]. Br J Dermatol, 2006, 155(1):160-169.
  • 3Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases[J]. Ann Rheum Dis, 2006, 65(Suppl3): iii2-iii15.
  • 4Thurber M, Feasel A, Stroehlein J, et al. Pustular psoriasis induced by infliximab[J]. J Drugs Dermatol, 2004, 3(4):439-440.
  • 5Sfikakis PP, Iliopoulas A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction[J]. Arthritis Rheum, 2005, 52(8):2513-2518.
  • 6Sari I, Akar S, Birlik M, et al. Anti-tumor necrosis factor-alpha-induced psoriasis[J]. J Rheumatol, 2006, 33(7):1411-1414.
  • 7Roux CH, Brocq O, Leccia N, et al. New-onset psoriatic palmo-plantaris pustulosis following infliximab therapy:A class effect? [J]. J Rheumatol, 2007, 34(2):434-437.
  • 8Cohen JD, Bournerias I, Buffar V, et al. Psoriasis induced by tumor necrosis factor-a antagonist therapy: a case series[J]. J Rheumatol, 2007, 34(2):380-385.
  • 9Goiriz R, Dauden E, Perez-Gala S, et al. Flare and change of psoriasis morphology during the course of treatment with tumor necrosis factor blockers[J]. Clin Exp Dermatol, 2007, 32(2): 176-179.
  • 10Dutz JP. Tumor necrosis factor-α inhibition and palmoplantar pustulosis: Janus-faced therapy?[J]. J Rheumatol,2007, 34(2):247-249.

共引文献2

同被引文献39

  • 1王莉莎,黄烽,张江林,邓小虎,张亚美,张莉芸,郭军华.肿瘤坏死因子拮抗剂在治疗强直性脊柱炎中的安全性分析[J].中国新药杂志,2007,16(7):556-561. 被引量：24
  • 2Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol, 2012, 24(9): 1078-1085.
  • 3Wee JS, Petrof G, Jackson K, et al. Infliximab for the treatment of psoriasis in the U.K.: 9 years" experience of infusion reactions at a single centre. Br J Dermatol, 2012, 167(2): 411-416.
  • 4Kerbleski JF, Gottlieb AB.Dermatological complications and safety of anti-TNF treatments. Gut, 2009, 58(8): 1033-1039.
  • 5Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol, 2009, 61(3): 486-504.
  • 6Papadavid E, Makris M, Dalamaga M, et al. Recall injection-site reactions to etanercept in a patient with psoriasis. Clin Exp Dermatol, 2009, 34(3): 414-415.
  • 7Bavbek S, Aydln O, Ataman S, et al. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy, 2011, 66(9): 1256-1257.
  • 8Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-bloekade therapy: a review and analysis of 127 cases. J Dermatolog Treat, 2009, 20(2): 100-108.
  • 9Harrison M J, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti- tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis, 2009, 68(2): 209-215.
  • 10Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum, 2010, 40 (3): 233-240.

引证文献2

二级引证文献2

中华风湿病学杂志
2010年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部